Drugs that contain Sofosbuvir; Velpatasvir
1. List of Epclusa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(6 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(6 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(7 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(7 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
|
US8334270
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US9085573
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8735372
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8580765
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(6 years from now) | |
|
US7964580
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(6 years from now) | |
|
US8889159
(Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(6 years from now) | |
|
US8633309
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(6 years from now) | |
|
US9284342
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(7 years from now) | |
|
US8618076
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(8 years from now) | |
|
US8940718
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
|
US8921341
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
|
US8575135
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
| US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
| US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
|
US11116783
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
|
US10086011
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
|
US9757406
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
| M (M) | Apr 27, 2025 |
| Pediatric Exclusivity (PED) | Dec 10, 2028 |
Market Authorisation Date: 10 June, 2021
Treatment: For the treatment of hepatitis c
Dosage: PELLETS;ORAL
EPCLUSA family patents
92
United States
31
Japan
31
European Union
22
Korea, Republic of
20
China
18
Hong Kong
18
Spain
18
Canada
17
New Zealand
16
Singapore
15
Australia
15
Portugal
13
Slovenia
13
Poland
13
Taiwan, Province of China
12
Israel
12
Mexico
12
EA
11
Brazil
10
Argentina
10
Chile
7
South Africa
7
Denmark
7
Hungary
7
Uruguay
7
Colombia
7
Croatia
7
Cyprus
6
Peru
6
Ecuador
5
Lithuania
5
Philippines
5
Costa Rica
5
RS
5
Ukraine
4
Russia
4
Moldova, Republic of
4
Malaysia
4
ME
3
Morocco
3
Germany
3
San Marino
1
Turkey
1
Norway
1
AP
1
Netherlands
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic